Global Crohn's Disease Therapeutics Market Size study, by Treatment (Medication [Anti-inflammatory Agents, Immunosuppressants, Antibiotics, Antipyretics], Nutritional Therapy, Surgery), Dosage Form (Oral, Parenteral), Age Group, End-use, and Regional Forecasts 2022-2032
The Global Crohn’s Disease Therapeutics Market is valued at approximately USD 13.3 billion in 2023 and is projected to expand at a compound annual growth rate of more than 4.00% from 2024 to 2032. Crohn’s disease, a chronic inflammatory bowel condition with often unpredictable flare-ups, has emerged as a serious healthcare challenge, disrupting the lives of millions globally. As its etiology remains elusive and no known cure exists, therapeutic approaches have evolved to mitigate symptoms, reduce inflammation, and maintain remission. In recent years, pharmaceutical advances have enabled a shift from reactive, symptom-oriented treatment strategies to proactive regimens that are rooted in biologic innovations, personalized immunomodulation, and patient-centric disease management. The focus is increasingly moving toward precision medicine—tailoring therapy based on genetic, microbial, and lifestyle factors to achieve more durable responses with fewer side effects.
This growth trajectory is being catalyzed by several structural drivers. Notably, rising prevalence of Crohn’s disease, particularly in North America and Western Europe, coupled with greater awareness and improved diagnostic capabilities, has significantly widened the treatment-seeking population. Concurrently, innovation in biologics and biosimilars has redefined the treatment landscape, offering powerful immunosuppressants and targeted monoclonal antibodies that deliver enhanced therapeutic value. Moreover, as healthcare systems recognize the long-term cost burden of poorly managed inflammatory bowel disease (IBD), there is a strategic emphasis on early intervention using high-efficacy agents. Clinical trials are increasingly focused on improving mucosal healing and achieving steroid-free remission, reflecting a market-wide transition toward value-based therapeutic outcomes.
Nonetheless, the market faces enduring obstacles. Chief among them are the exorbitant costs of biologic therapies and the limited access to advanced care in low-income countries. Regulatory and reimbursement hurdles remain formidable, particularly for newer entrants in the biosimilar space. Additionally, the variability in individual patient response and the chronic nature of the disease necessitate continuous treatment adjustments, often leading to high switching rates and patient dissatisfaction. Despite these challenges, there is growing investment in next-generation therapies—including small-molecule drugs and microbiome-based treatments—that promise to disrupt the current biologics-dominated paradigm.
From a regional perspective, North America dominates the market share, driven by high disease incidence, favorable reimbursement policies, and a robust pharmaceutical R&D ecosystem. The United States, in particular, leads in both clinical development and early adoption of innovative therapeutics. Europe follows closely, with strong healthcare infrastructure and government-led support for chronic disease management. Meanwhile, the Asia Pacific region is anticipated to record the highest growth rate over the forecast period, propelled by expanding healthcare access, rising awareness campaigns, and strategic market entries by global pharmaceutical firms. Latin America and the Middle East & Africa are witnessing steady improvements, underpinned by growing collaborations with international health bodies and increasing public health investments.
Major market player included in this report are:
By Treatment
– Immunosuppressants
– Antibiotics
– Antipyretics
North America
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
This growth trajectory is being catalyzed by several structural drivers. Notably, rising prevalence of Crohn’s disease, particularly in North America and Western Europe, coupled with greater awareness and improved diagnostic capabilities, has significantly widened the treatment-seeking population. Concurrently, innovation in biologics and biosimilars has redefined the treatment landscape, offering powerful immunosuppressants and targeted monoclonal antibodies that deliver enhanced therapeutic value. Moreover, as healthcare systems recognize the long-term cost burden of poorly managed inflammatory bowel disease (IBD), there is a strategic emphasis on early intervention using high-efficacy agents. Clinical trials are increasingly focused on improving mucosal healing and achieving steroid-free remission, reflecting a market-wide transition toward value-based therapeutic outcomes.
Nonetheless, the market faces enduring obstacles. Chief among them are the exorbitant costs of biologic therapies and the limited access to advanced care in low-income countries. Regulatory and reimbursement hurdles remain formidable, particularly for newer entrants in the biosimilar space. Additionally, the variability in individual patient response and the chronic nature of the disease necessitate continuous treatment adjustments, often leading to high switching rates and patient dissatisfaction. Despite these challenges, there is growing investment in next-generation therapies—including small-molecule drugs and microbiome-based treatments—that promise to disrupt the current biologics-dominated paradigm.
From a regional perspective, North America dominates the market share, driven by high disease incidence, favorable reimbursement policies, and a robust pharmaceutical R&D ecosystem. The United States, in particular, leads in both clinical development and early adoption of innovative therapeutics. Europe follows closely, with strong healthcare infrastructure and government-led support for chronic disease management. Meanwhile, the Asia Pacific region is anticipated to record the highest growth rate over the forecast period, propelled by expanding healthcare access, rising awareness campaigns, and strategic market entries by global pharmaceutical firms. Latin America and the Middle East & Africa are witnessing steady improvements, underpinned by growing collaborations with international health bodies and increasing public health investments.
Major market player included in this report are:
- AbbVie Inc.
- Johnson & Johnson
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Novartis AG
- UCB S.A.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Biogen Inc.
- F. Hoffmann-La Roche Ltd
- Amgen Inc.
- AstraZeneca PLC
- Sanofi S.A.
By Treatment
- Medication
– Immunosuppressants
– Antibiotics
– Antipyretics
- Nutritional Therapy
- Surgery
- Oral
- Parenteral
- Pediatric
- Adult
- Geriatric
- Hospitals
- Clinics
- Homecare Settings
- Others
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- ROE
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Brazil
- Mexico
- Saudi Arabia
- South Africa
- RoMEA
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET EXECUTIVE SUMMARY
1.1. Global Crohn’s Disease Therapeutics Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Treatment
1.3.2. By Dosage Form
1.3.3. By Age Group
1.3.4. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Payer & Patient Perspectives)
2.3.4. Demand Side Analysis
2.3.4.1. Diagnostic Improvements & Early Screening
2.3.4.2. Technological Advancements in Biologics & Small Molecules
2.3.4.3. Patient Awareness & Disease Management Programs
2.4. Estimation Methodology
2.5. Years Considered for the Study
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Prevalence and Improved Diagnostic Capabilities
3.1.2. Innovation in Biologics and Biosimilars
3.1.3. Emphasis on Value-Based Early Intervention
3.2. Market Challenges
3.2.1. High Cost Burden and Access Barriers
3.2.2. Regulatory and Reimbursement Complexities
3.2.3. Patient Heterogeneity and Treatment Switching
3.3. Market Opportunities
3.3.1. Development of Small-Molecule and Microbiome-Based Therapies
3.3.2. Expansion in Asia Pacific and Emerging Economies
3.3.3. Public–Private R&D Collaborations
CHAPTER 4. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY TREATMENT 2022–2032
5.1. Segment Dashboard
5.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Medication
– Anti-inflammatory Agents
– Immunosuppressants
– Antibiotics
– Antipyretics
5.2.2. Nutritional Therapy
5.2.3. Surgery
CHAPTER 6. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY DOSAGE FORM 2022–2032
6.1. Segment Dashboard
6.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oral
6.2.2. Parenteral
CHAPTER 7. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY AGE GROUP 2022–2032
7.1. Segment Dashboard
7.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Pediatric
7.2.2. Adult
7.2.3. Geriatric
CHAPTER 8. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY END-USE 2022–2032
8.1. Segment Dashboard
8.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Homecare Settings
8.2.4. Others
CHAPTER 9. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022–2032
9.1. North America
9.1.1. U.S.
9.1.1.1. Treatment breakdown, 2022–2032
9.1.1.2. End-use breakdown, 2022–2032
9.1.2. Canada
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. AbbVie Inc.
10.1.2. Johnson & Johnson
10.1.3. Pfizer Inc.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. AbbVie Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Johnson & Johnson
10.3.3. Pfizer Inc.
10.3.4. Takeda Pharmaceutical Company Limited
10.3.5. Novartis AG
10.3.6. UCB S.A.
10.3.7. Eli Lilly and Company
10.3.8. Bristol-Myers Squibb Company
10.3.9. GlaxoSmithKline plc
10.3.10. Merck & Co., Inc.
10.3.11. Biogen Inc.
10.3.12. F. Hoffmann-La Roche Ltd
10.3.13. Amgen Inc.
10.3.14. AstraZeneca PLC
10.3.15. Sanofi S.A.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
1.1. Global Crohn’s Disease Therapeutics Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Treatment
1.3.2. By Dosage Form
1.3.3. By Age Group
1.3.4. By End-use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Payer & Patient Perspectives)
2.3.4. Demand Side Analysis
2.3.4.1. Diagnostic Improvements & Early Screening
2.3.4.2. Technological Advancements in Biologics & Small Molecules
2.3.4.3. Patient Awareness & Disease Management Programs
2.4. Estimation Methodology
2.5. Years Considered for the Study
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Prevalence and Improved Diagnostic Capabilities
3.1.2. Innovation in Biologics and Biosimilars
3.1.3. Emphasis on Value-Based Early Intervention
3.2. Market Challenges
3.2.1. High Cost Burden and Access Barriers
3.2.2. Regulatory and Reimbursement Complexities
3.2.3. Patient Heterogeneity and Treatment Switching
3.3. Market Opportunities
3.3.1. Development of Small-Molecule and Microbiome-Based Therapies
3.3.2. Expansion in Asia Pacific and Emerging Economies
3.3.3. Public–Private R&D Collaborations
CHAPTER 4. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY TREATMENT 2022–2032
5.1. Segment Dashboard
5.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Medication
– Anti-inflammatory Agents
– Immunosuppressants
– Antibiotics
– Antipyretics
5.2.2. Nutritional Therapy
5.2.3. Surgery
CHAPTER 6. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY DOSAGE FORM 2022–2032
6.1. Segment Dashboard
6.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oral
6.2.2. Parenteral
CHAPTER 7. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY AGE GROUP 2022–2032
7.1. Segment Dashboard
7.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Pediatric
7.2.2. Adult
7.2.3. Geriatric
CHAPTER 8. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY END-USE 2022–2032
8.1. Segment Dashboard
8.2. Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Homecare Settings
8.2.4. Others
CHAPTER 9. GLOBAL CROHN’S DISEASE THERAPEUTICS MARKET SIZE & FORECASTS BY REGION 2022–2032
9.1. North America
9.1.1. U.S.
9.1.1.1. Treatment breakdown, 2022–2032
9.1.1.2. End-use breakdown, 2022–2032
9.1.2. Canada
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. AbbVie Inc.
10.1.2. Johnson & Johnson
10.1.3. Pfizer Inc.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. AbbVie Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Johnson & Johnson
10.3.3. Pfizer Inc.
10.3.4. Takeda Pharmaceutical Company Limited
10.3.5. Novartis AG
10.3.6. UCB S.A.
10.3.7. Eli Lilly and Company
10.3.8. Bristol-Myers Squibb Company
10.3.9. GlaxoSmithKline plc
10.3.10. Merck & Co., Inc.
10.3.11. Biogen Inc.
10.3.12. F. Hoffmann-La Roche Ltd
10.3.13. Amgen Inc.
10.3.14. AstraZeneca PLC
10.3.15. Sanofi S.A.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
